Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130
- PMID: 8376957
- DOI: 10.1099/0022-1317-74-9-1757
Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130
Abstract
Rhesus macaques were immunized with purified virus-derived simian immunodeficiency virus of macaques (SIVmac) 251/32H glycoprotein 130 (gp130) or primed with recombinant vaccinia virus (VV) expressing the env gene of the SIVmac BK28 clone and boosted subsequently with virus-derived gp130. High antibody titres of at least 10(4) against recombinant gp140 were induced with both vaccines. Analysis of the antibody specificity with a peptide ELISA revealed that different linear epitopes were recognized after administration of virus-derived gp130 compared with those after priming with VV. Antibodies to some epitopes (peptides 10 and 49), which were also found in SIV-infected animals, were induced with both vaccines, whereas antibodies to other regions were induced by only one vaccine preparation. The analysis of the helper T cell response revealed a poor immunogenicity of the virus-derived gp130, whereas priming with VV induced a considerable helper T cell activity in all three vaccinees after the second VV infection. Using synthetic peptides, several epitopes were identified. Our observations show that immunization with a virus-derived gp130 or live recombinant VV induces a considerably different antibody and helper T cell response. These differences in immunogenicity might have important implications for further vaccine development.
Similar articles
-
Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S27-32. AIDS Res Hum Retroviruses. 1994. PMID: 7865316
-
Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo.Virology. 1996 Feb 15;216(2):444-50. doi: 10.1006/viro.1996.0082. Virology. 1996. PMID: 8607276
-
Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.J Virol. 1993 Jan;67(1):577-83. doi: 10.1128/JVI.67.1.577-583.1993. J Virol. 1993. PMID: 8416384 Free PMC article.
-
Simian immunodeficiency virus-specific cytotoxic T lymphocytes in rhesus monkeys: characterization and vaccine induction.Semin Immunol. 1993 Jun;5(3):215-23. doi: 10.1006/smim.1993.1025. Semin Immunol. 1993. PMID: 8394161 Review.
-
Modern vaccines. Human immunodeficiency virus and AIDS: challenges and progress.Lancet. 1990 May 5;335(8697):1081-4. doi: 10.1016/0140-6736(90)92645-x. Lancet. 1990. PMID: 1970381 Review. No abstract available.
Cited by
-
Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.J Virol. 1997 Dec;71(12):9475-81. doi: 10.1128/JVI.71.12.9475-9481.1997. J Virol. 1997. PMID: 9371609 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources